(Q51560788)

7 April 2018

title

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. (English)

1 reference

7 April 2018

0 references

Damsbo P

1

1 reference

7 April 2018

Marbury TC

2

1 reference

7 April 2018

Hatorp V

3

1 reference

7 April 2018

Clauson P

4

1 reference

7 April 2018

Müller PG

5

1 reference

7 April 2018

publication date

1 August 1999

1 reference

7 April 2018

Diabetes Research and Clinical Practice

published in

1 reference

7 April 2018

volume

45

1 reference

7 April 2018

issue

1

1 reference

7 April 2018

page(s)

31-39

1 reference

7 April 2018

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

The pathogenesis of type II diabetes mellitus. A polygenic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900057-1

7 January 2021

10.1016/S0168-8227(99)00057-1

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018